Analysis and Synthesis of Bulk Drugs and Pharmaceutical Formulations
IDIQ
Overview
Ceiling
$12,069,385
Primary Sponsoring Agency
Who Can Use
One Agency
Primary NAICS
Primary Set Aside
None
Extent Competed
Full And Open Competition
Analysis and Synthesis of Bulk Drugs and Pharmaceutical Formulations awarded by National Cancer Institute (NCI) in April 2023 accepts orders through April 2028.
The IDIQ has a reported ceiling of $12,069,385, and as of today, $0 has been obligated through the vehicle.
The IDIQ was awarded
full & open and has a primary NAICS code of 325412.
Status
Period of Performance
4/11/23
Start Date
4/10/28
Ordering Period End Date
Task Order Obligations
$0
Total Obligated
$0
Current Award
$0
Potential Award
Awardees
Analysis and Synthesis of Bulk Drugs and Pharmaceutical Formulations awardees
Contract Awards
Analysis and Synthesis of Bulk Drugs and Pharmaceutical Formulations task orders
Subcontract Awards